Seattle, WA /PRNewswire/ -- Coherent Market Insights (CMI), a market intelligence and consulting firm, offers a unique database to the biopharmaceutical industry - PHASE-XS. It provides clinical trial analysis (Phase 3 and Phase 4), conducted in the U.S. and other countries (based on client's request), by tracking more than 30 critical parameters, enabling detailed analysis for the clients.
PHASE-XS is a blend of clinical, market, and competition insights. Thus, offering a range of insights on pipeline products.
Biologics are more target specific than small molecules and thus, are meant to have a lower toxicity profile. While biologics tend to improve patient outcomes, biosimilars tend to increase competition and patient accessibility to newer therapies. Countries like India have shown a trajectory growth in terms of product development and launches in the biosimilar space. This trend seems to show growth in the future with more and more targeted therapies being developed, leading to new biologics, thus opening up opportunities for biosimilars. Even contract research organizations (CROs) and contract manufacturing organizations (CMOs) are investing in expansion of their production capacities for biologics/biosimilars.
Get in touch to know more about Phase-XS @ https://www.coherentmarketinsights.com/phasexs-enquiry
Sanofi has invested nearly 4 billion Euros in the biologics' production space since 2012. The company intends to increase its share of biologics in the pipeline further from 60% in 2016. Besides, the number of biologic IPOs in the U.S. has increased drastically over the past 5-7 years. Investors are ready to take risks in these high return therapies.
Coherent Market Insights, through its PHASE_XS offering, intends to help companies already investing, or willing to invest in biologic and biosimilar space, get a futuristic market purview to help gauge their investment values and expected returns. Key insights offered by PHASE-XS include:
- New biologics/biosimilars
- Technology of biologics/biosimilars
- New indications for approved biologics
- Most active companies in the market
- Number of approved drugs in respective drug class
- Major competitor drugs
- Method of administration
- Market potential
- Market size
- Identify white spaces
- Identify products with significant revenue opportunity
Know more about PHASE-XS @ https://www.coherentmarketinsights.com/phasexs/
By 2020, biologics are expected to account for a quarter of the pharmaceutical market. Therefore, it is quite essential to understand this segment and its competition.
Research Reports on Biologics and Biosimilars:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.